As previously reported, Argus downgraded Elevance Health (ELV) to Hold from Buy, citing the ongoing pressures on the company’s profit margins from medical cost trends in its Medicaid and ACA marketplace businesses. The firm sees the path to margin recovery taking longer than it had previously expected and is reducing its EPS estimates for both 2025 and 2026, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health downgraded to Hold from Buy at Argus
- Elevance Health: Buy Rating Affirmed Amid Growth Potential in Non-HIX Segments and Temporary Earnings Boosts
- Insider Moves: Seagate, Elevance, Appian, AeroVironment, Box
- JPMorgan, Starbucks, HPE, Sarepta, Elevance: Trending by Analysts
- Elevance Health CEO Boudreaux buys $2.44M of shares